Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyCapital Bluecross HCT in ALL Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy MP 9.041

    Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

    Customize your policy alerts

    Sign up for Capital Bluecross Policy MP 9.041 alerts

    Get alerted when Policy MP 9.041 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage policy for autologous and allogeneic hematopoietic cell transplantation (HCT) for childhood and adult acute lymphoblastic leukemia (ALL), specifying when HCT is considered medically necessary and outlining risk stratification and conditioning considerations for providers and prior authorization reviewers.

    Policy Summary
    PayerCapital Bluecross
    PolicyHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
    Policy CodePolicy MP 9.041
    Change TypeMinor review — no material clinical or coverage changes
    Effective DateMay 1, 2026
    Last ReviewJan 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization to confirm indication and provide documentation of remission status, donor type, and conditioning regimen.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    First remission high-riskFirst remission high-risk
    Second+Second or greater remission
    RICRIC eligible
    Covered when medically necessaryCodes listed
    35+Evidence cited

    Coverage Criteria for Hematopoietic Cell Transplantation (HCT) in ALL

    inv-01: Childhood ALL — Covered Indications

    Covered when ANY of the following are met:

    childhood_coverage: Autologous or allogeneic HCT may be considered medically necessary to treat childhood ALL in first complete remission but at high risk of relapse (see Policy Guidelines for high-risk factors).

    See Policy Guidelines for high-risk definitions.

    childhood_coverage: Autologous or allogeneic HCT may be considered medically necessary to treat childhood ALL in second or greater remission or refractory ALL.
    childhood_coverage: Allogeneic HCT may be considered medically necessary to treat relapsing ALL after a prior autologous HCT in children.

    inv-02: Adult ALL — Covered and Not Covered Indications

    Covered when specified criteria are met; investigational where noted:

    adult_coverage: Autologous HCT may be considered medically necessary to treat adult ALL in first complete remission but at high risk of relapse (see Policy Guidelines for high-risk factors).
    adult_coverage: Allogeneic HCT may be considered medically necessary to treat adult ALL in first complete remission for any risk level (see Policy Guidelines for risk factors).
    adult_coverage: Allogeneic HCT may be considered medically necessary to treat adult ALL in second or greater remission, or in adults with relapsed or refractory ALL.
    adult_coverage: Reduced-intensity conditioning allogeneic HCT may be considered medically necessary for patients in complete marrow and extramedullary first or second remission who, for medical reasons, would be unable to tolerate a standard myeloablative conditioning regimen.

    See Policy Guidelines for medical reasons.

    adult_investigational:

    inv-03: Indications supported by evidence

    Covered when evidence supports meaningful improvement in net health outcome for these patient groups:

    Pediatric ALL: Children with high-risk ALL in first complete remission (CR1) or with relapsed ALL: HCT (autologous or allogeneic) has been associated with fewer relapses though higher treatment-related mortality; for subsets (e.g., second complete remission or beyond or relapsed disease) autologous or allogeneic HCT is a treatment option supported by RCTs, systematic reviews, and ASBMT statements.

    Supported by RCTs, systematic reviews, and ASBMT position statements.

    Adult ALL - Autologous HCT: Adults with high-risk ALL in CR1 whose health status is sufficient to tolerate the procedure: autologous HCT is supported by RCTs and systematic reviews and may meaningfully improve net health outcome.
    Adult ALL - Allogeneic HCT: Myeloablative allogeneic HCT is supported for adults with any-risk ALL who can tolerate the procedure; reduced-intensity conditioning allogeneic HCT may be considered for patients in complete marrow and extramedullary first or second remission who would not tolerate myeloablative conditioning.

    inv-04: Insufficient evidence

    Not enough evidence to determine benefit:

    Relapse after prior autologous HCT: For individuals who relapse after prior autologous HCT for ALL and who receive allo-HCT, evidence is limited to small case series with short follow-up and is inadequate to determine benefit.

    Evidence reviews identified only small case series with short-term follow-up.

    Autologous hematopoietic cell transplantation (HCT) for adults with acute lymphoblastic leukemia (ALL) in second or greater complete remission or with refractory disease is designated investigational. The policy states there is insufficient evidence to support a general conclusion that autologous HCT improves health outcomes in these adult patient groups, and therefore such requests may be denied as investigational.

    The policy does not list broad categorical exclusions, but it implies that patients who are unable to tolerate conditioning regimens (for example, myeloablative conditioning) because of age, comorbidities, or poor performance status are not candidates for those higher‑intensity approaches. In such cases, conditioning intensity and overall transplant candidacy should be documented and alternatives (including reduced‑intensity conditioning) considered per the Policy Guidelines.

    No explicit exclusions are stated in the provided policy history and administrative notes. Policy updates and consensus reviews are documented, but they do not add or specify new blanket exclusions in the cited sections.

    For patients who relapse after a prior autologous HCT and are being considered for allogeneic HCT, the evidence is limited to small case series with short follow‑up. The policy concludes that the available data are insufficient to determine benefit for allo‑HCT in this setting, and therefore effectiveness is not established.

    The provided policy history and administrative sections do not contain explicit statements using the phrase ‘not medically necessary’ for specific scenarios in the cited chunks. Operational and administrative notes record reviews and reference updates but do not add new not‑medically‑necessary declarations in these excerpts.

    Conditioning Regimens and Intensity

    RegimenIndication / patient selectionCoverage stance
    Reduced-intensity conditioning (RIC) allogeneic HCTPatients unable to tolerate standard myeloablative conditioning due to age (typically >60 years) or comorbidities (e.g., liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status)Reduced-intensity conditioning allogeneic HCT may be considered medically necessary when patient cannot tolerate myeloablative conditioning
    ApproachDescriptionWhen to use / recommendation
    Myeloablative conditioning (conventional)Intense regimens using cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without high-dose radiotherapy intended to cause marrow ablation; provides tumor eradication plus graft-versus-malignancy effect but with higher treatment-related toxicityRecommended when patient’s health status is sufficient to tolerate full myeloablative conditioning
    Reduced-intensity conditioning (RIC)Pretransplant regimens using lower doses of cytotoxic drugs or less intense radiotherapy intended to be nonmyeloablative to reduce treatment-related morbidity and nonrelapse mortality while enabling graft-versus-malignancy effects; intensity ranges from near-myeloablative to minimally myeloablative with lymphoablationConsider for patients who cannot tolerate full myeloablative conditioning due to age, comorbidity, or poor performance status
    Study / sourcePopulation & comparisonKey point cited
    Abdul Wahid SF et al., meta-analysis (Stem Cells Dev. 2014) [cited]Adults with acute leukemias (including AML and ALL): compared reduced-intensity vs myeloablative conditioningComparative syntheses examining RIC versus myeloablative conditioning summarized outcomes across studies
    Mohty M et al., retrospective EBMT study (Haematologica. 2008) [cited]Adult patients with ALL receiving reduced-intensity conditioning allogeneic SCT (retrospective cohort)Reports RIC as a potential therapeutic approach for adults with ALL in remission
    Pulsipher MA et al., Pediatric Blood and Marrow Transplant Consortium Study ONC0313 (Blood. 2009) [cited]Pediatric patients ineligible for myeloablative therapy receiving reduced-intensity allogeneic transplantationProvides evidence for RIC use in pediatric patients ineligible for myeloablative regimens

    Line of Therapy Considerations

    inv-31: first-line

    first_remission_high_risk: HCT may be considered medically necessary in first complete remission for patients at high risk of relapse (see Policy Guidelines for high-risk features).

    Children: see Policy Guidelines; Adults: see Policy Guidelines.

    inv-32: salvage

    second_or_greater_remission_or_refractory: Autologous or allogeneic HCT may be considered medically necessary in second or greater remission or refractory ALL in children; allogeneic HCT may be considered medically necessary in adult second or greater remission or relapsed/refractory disease. Autologous HCT in adults for these indications is investigational.

    inv-33: first-line

    CR1_high_risk:

    Biomarkers and Genetic Risk Factors

    BCR-ABL1 / Philadelphia chromosome (t[9;22]) — biomarker requirement / significance
    BiomarkerBCR-ABL1 / Philadelphia chromosome (t[9;22])
    Clinical significanceIdentified as an adverse prognostic factor that can place patients (children and adults) into a high-risk category supporting consideration of HCT in first complete remission
    Policy cross-referenceSee MP 2.317 for BCR-ABL1 testing guidance
    Philadelphia chromosome (BCR-ABL) — listed as high-importance biomarker
    BiomarkerPhiladelphia chromosome (BCR-ABL)
    Role in policyMentioned in cited studies and evidence summaries as relevant to transplant outcomes and indications for HCT

    Procedure and Diagnosis Codes

    Covered procedure codesmixedCovered
    S2140listed in procedure codes
    S2142listed in procedure codes
    S2150listed in procedure codes
    38204listed in procedure codes
    38205listed in procedure codes
    38206listed in procedure codes
    38207listed in procedure codes
    38208listed in procedure codes
    38209listed in procedure codes
    38210listed in procedure codes
    1–10 of 19
    1/2
    Covered diagnosis codes (ICD-10)ICD-10Covered
    C91.00Acute lymphoblastic leukemia not having achieved remission
    C91.01Acute lymphoblastic leukemia, in remission
    C91.02Acute lymphoblastic leukemia, in relapse

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Obtain prior authorization to confirm indication and conditioning rationale

    Prior authorization is required to confirm the indication for HCT (e.g., first complete remission with high-risk features, second or greater remission, refractory disease, or relapse after prior autologous HCT) and to document donor type and conditioning approach, including rationale for reduced-intensity conditioning when used.

    • Confirm line of therapy and remission status (CR1 with high-risk features, CR2+, refractory, or relapse after prior autologous HCT).
    • Document donor type (autologous vs allogeneic) and HLA matching details.
    • Provide rationale for conditioning approach and, if applicable, reasons reduced-intensity conditioning is chosen.
    Billing Rule

    Definitions

    HCT — Definition of hematopoietic cell transplantation
    DefinitionHematopoietic cell transplantation (HCT) is a procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function after marrow-toxic cytotoxic therapy with or without whole-body radiotherapy.
    Cell sourcesStem cells may be obtained from the recipient (autologous) or a donor (allogeneic) and harvested from bone marrow, peripheral blood, or umbilical cord blood.
    Indication contextUsed to restore marrow and immune function in patients receiving bone marrow–toxic doses of cytotoxic drugs and/or radiotherapy.
    HLA match — Definition and donor matching considerations
    DefinitionHLA match refers to compatibility established by typing human leukocyte antigens at HLA-A, -B, and -DR loci.
    Ideal donors

    Background and Rationale

    Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic subtypes and prognostic factors that guide risk‑adapted management. Hematopoietic cell transplantation (HCT) — either autologous or allogeneic — is used selectively as part of that risk‑adapted strategy: for example, HCT may be considered for children and adults in first complete remission when at high risk of relapse, for patients in second or greater remission, and for relapsed or refractory disease in appropriate candidates. The balance of potential benefit (reduced relapse) and harms (higher treatment‑related mortality) is emphasized in the evidence summaries and underlies the policy’s differentiated recommendations.

    Evidence Summary and References

    The policy cites multiple primary studies, meta‑analyses, and guideline documents to support its conclusions. Representative references include randomized controlled trials and systematic reviews (for example, Cochrane and meta‑analyses), retrospective series of reduced‑intensity conditioning, and guideline sources such as NCCN and ASBMT/ASTCT guidance. These references are listed in the policy’s reference section to support the stated evidence summaries and recommendations.

    Where evidence supports clinically meaningful improvement in net health outcome, the policy identifies first‑line and salvage indications for HCT. Examples include: autologous or allogeneic HCT for children with high‑risk ALL in first complete remission or with relapsed disease; autologous HCT for adults with high‑risk ALL in first complete remission when the patient can tolerate the procedure; and myeloablative allogeneic HCT for adults with ALL who can tolerate the regimen. The policy also recognizes reduced‑intensity conditioning (RIC) allogeneic HCT as an option for patients in complete marrow and extramedullary first or second remission who cannot tolerate standard myeloablative conditioning.

    Revision History

    2026-05-01policy_effective_dateLatest

    Policy effective date for MP 9.041 updated to 2026-05-01.

    2026-01-21consensus_review

    Consensus review completed with no change to policy intent; policy updated.

    2025-01-21consensus_review
    Policy Summary
    PayerCapital Bluecross
    PolicyHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
    Policy CodePolicy MP 9.041
    Change TypeMinor review — no material clinical or coverage changes
    Effective DateMay 1, 2026
    Last ReviewJan 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization to confirm indication and provide documentation of remission status, donor type, and conditioning regimen.
    SourceLink
    On This Page
    Coverage Criteria for Hematopoietic Cell Transplantation (HCT) in ALLConditioning Regimens and IntensityLine of Therapy ConsiderationsBiomarkers and Genetic Risk FactorsProcedure and Diagnosis CodesProvider Actions, Prior Authorization, and DocumentationDefinitionsBackground and RationaleEvidence Summary and ReferencesRevision History
    Autologous HCT is investigational to treat adult ALL in second or greater remission or those with refractory disease due to insufficient evidence to support a general conclusion of benefit.

    Requests for these indications may be denied as investigational per policy.

    HCT (autologous or allogeneic) may be considered for high-risk patients in first complete remission where evidence shows benefit in relapse reduction and for some subgroups improved net health outcome.

    Supported by RCTs, systematic reviews, and ASBMT position statements.

    inv-34: salvage

    Relapsed_or_refractory: Allogeneic HCT may be an option for relapsed or refractory disease; autologous HCT may be considered for some relapsed patients, particularly in second remission or beyond, though evidence is limited for certain post-autologous relapse scenarios.

    inv-35: first-line

    first_line_evidence: Multiple trials and meta-analyses address allogeneic transplantation in first complete remission for high-risk or selected adult patients, including comparisons of allogeneic versus autologous transplantation and versus chemotherapy, supporting transplant consideration in these settings.

    References include meta-analyses and randomized trials.

    Associated evidenceReferenced in multiple trials and reviews comparing allogeneic versus autologous transplantation and outcomes in Ph+ ALL

    Include listed procedure and diagnosis codes in authorization submissions

    Use the procedure and diagnosis codes listed in the policy’s coding section when submitting prior authorization requests to support medical necessity determinations.

    • Procedure codes listed: S2140, S2142, S2150, 38204–38215, 38230, 38232, 38240–38241 (as listed).
    • Diagnosis/ICD-10 codes listed: C91.00, C91.01, C91.02.
    • Note: identification of a code does not by itself denote coverage; coverage determined by member benefit and medical necessity.
    Prior Authorization

    Summary: prior authorization requirement (no extra operational steps listed)

    Prior authorization is required as described in the policy; no additional explicit operational prior authorization steps are specified in these sections of the document.

    • Follow standard prior authorization processes; the policy text does not add extra operational submission steps beyond documentation of indication and coding.
    Step Therapy

    No step therapy sequencing specified

    The policy does not specify any step therapy sequencing or required prior treatments before HCT.

    • No mandated prior disease-modifying therapy sequence is described in these policy sections.
    Step Therapy

    No step therapy requirements in this section

    No step therapy requirements for HCT are specified in the policy text cited.

    • Coverage is determined by member benefit, eligibility, and medical necessity rather than a step-therapy algorithm in this policy.
    Step Therapy

    No step therapy requirements described

    There are no step therapy requirements described in the provided policy text for HCT.

    • Policy history and administrative notes do not introduce step therapy sequencing.
    Documentation Required

    Include disease status, risk factors, donor match, and conditioning details in documentation

    Documentation submitted for authorization should include disease status (remission number; relapsed or refractory status), risk-stratification factors, donor matching, and conditioning-intensity rationale to support medical necessity.

    • Specify remission status (CR1 with high-risk features, CR2+, refractory, or relapse).
    • Provide risk factors used for stratification (age, WBC, genetic abnormalities such as t(9;22) or t(4;11), MRD status) where applicable.
    • Include donor HLA matching information and chosen conditioning intensity (myeloablative vs reduced-intensity) with justification.
    Billing Rule

    Provide listed codes and supporting documentation with requests

    Coding and documentation should reference the policy’s listed procedure and diagnosis codes and the policy note that code identification does not by itself guarantee coverage.

    • Attach applicable procedure codes (e.g., S2140, S2142, S2150, 38204–38241 series) and diagnosis codes (C91.00, C91.01, C91.02) to requests.
    • Remember that code listing is informational; coverage depends on member benefits and documented medical necessity.
    Note

    Policy history provided; no additional operational steps

    Policy history and administrative notes are provided but do not add specific operational steps for providers beyond the policy’s clinical and documentation requirements.

    • Review policy history for updates, but follow the medical necessity and documentation requirements stated elsewhere in the policy for authorizations.
    Denial Risk

    Investigational: autologous HCT for adult CR2+ or refractory disease — potential denial risk

    Requests for autologous HCT in adults for second or greater remission or refractory disease may be denied as investigational under this policy.

    • Autologous HCT is explicitly stated as investigational for adult ALL in second or greater remission or refractory disease due to insufficient evidence of benefit.
    • Provide evidence or rationale if seeking approval for such cases, recognizing the policy stance.
    Denial Risk

    Verify eligibility, benefits, and medical necessity before proceeding

    Coverage and payment are subject to the member’s benefit program, eligibility on the date of service, and a determination that the services are medically necessary and appropriate.

    • Verify member eligibility and benefit coverage prior to scheduling/transplant.
    • Ensure documentation demonstrates medical necessity per policy criteria.
    Denial Risk

    No additional explicit denial triggers listed in these sections

    No explicit denial triggers beyond the policy’s stated investigational stance and standard eligibility/medical necessity determinations are identified in these sections.

    • Use the policy clinical criteria and documentation requirements to reduce risk of denial; policy history does not add other denial triggers.
    Ideal donors are HLA-identical siblings; matched unrelated donors identified through registries are the next option; related donors mismatched at one locus and haploidentical donors are alternatives.
    Clinical importanceHLA compatibility is a critical factor for successful allogeneic transplantation and affects graft-versus-host disease risk and outcomes.
    Hematopoietic cell transplantation (HCT) — procedural definition
    DefinitionHematopoietic cell transplantation (HCT) is the intravenous infusion of hematopoietic stem cells to restore marrow and immune function after marrow-toxic therapy; cells may be autologous or allogeneic and obtained from marrow, peripheral blood, or cord blood.
    Compatibility noteImmunologic compatibility is not an issue for autologous HCT but is critical for allogeneic HCT, established by HLA typing.
    Sources referencedCord blood transplantation and donor sources are discussed in evidence review sections of the policy.
    Allogeneic — definition and key points (graft-versus-host, donor cells)
    DefinitionAllogeneic transplantation uses donor cells (different genetic constitution from recipient) and requires HLA matching.
    Therapeutic effectsProvides potential graft-versus-tumor (graft-versus-leukemia) effect and lacks the risk of tumor contamination seen with autologous grafts.
    RisksCarries risk of graft-versus-host disease, which increases with greater HLA disparity and recipient age.
    Autologous — definition and typical use as consolidation
    DefinitionAutologous transplantation uses the patient’s own harvested stem cells and is typically performed as consolidation when disease is in complete remission.
    Clinical noteAutologous HCT does not involve immunologic compatibility concerns and is not associated with graft‑versus‑host disease.
    Policy stanceAutologous HCT is considered in certain high‑risk first remission settings; however, it is investigational for adults in second or greater remission or refractory disease per the policy.
    SourcePolicy definitions and medical policy sections describe autologous use and limitations.
    Reduced-intensity conditioning (RIC) — definition and purpose
    DefinitionReduced‑intensity conditioning (RIC) refers to pretransplant regimens using lower doses of cytotoxic drugs or less intense radiotherapy than traditional myeloablative conditioning, intended to be nonmyeloablative and reduce treatment‑related morbidity.
    PurposeRIC aims to reduce disease burden while minimizing treatment‑related morbidity and nonrelapse mortality during the period when graft‑versus‑malignancy effects develop.
    IndicationsConsidered for patients who cannot tolerate myeloablative conditioning due to age (typically >60 years), comorbidities, low performance status, or prior intensive therapy.
    NCCN/ASBMT guideline references — references to guideline sources for HCT in ALL
    Guideline sourcesNCCN Clinical Practice Guidelines in Oncology: Acute lymphoblastic leukemia (Version 2.2025) and Pediatric ALL (Version 1.2026)
    Specialty society guidanceASBMT/ASTCT guidance: Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy (Biol Blood Marrow Transplant. Jul 2020) and ASBMT 2019 evidence‑based review for adult ALL
    Additional referencesCMS National Coverage Determination and multiple systematic reviews and trials cited in the policy support HCT indications.

    Consensus review completed with no change to policy stance; policy updated.

    2024-11-20administrative_update

    Administrative update removing NCCN statement.

    2024-04-03consensus_review

    Consensus review completed with no change to policy statement; new references added.

    2023-02-13consensus_review

    Consensus review completed with no change to policy statement; new definitions and references added.

    2022-02-08consensus_review

    Language added during consensus review; references added with no change to policy statement.

    2021-03-01consensus_review

    Consensus review completed with no change to policy statement; policy guidelines, background, rationale, and references updated.

    2020-04-06consensus_review

    Consensus review completed with no change to policy statements; references updated and coding reviewed.